Polymeric drug delivery systems have achieved great developments in the last two decades. These formulations or devices enable the introduction of therapeutic substances into the body. Biodegradable and bio-reducible polymers are the best choice for several new drug delivery systems. To understand the future and practical applications of these biodegradable and bioreducible polymers, we require further exploration of the recent developments in the field. In recent years, pharmaceutical research has focused on the development of nanotechnology systems applicable indifferent fields of medicine, especially in drug delivery. Currently, the use of biopolymers as nanoparticles (NPs) represents an alternative system with a huge potential for the targeted distribution of drugs or biological macromolecules in the body. Many polymers are used in the synthesis of nanoparticles (NPs), namely, polylactic acid (PLA), poly lactic-co-glycolic acid (PLGA), and polyethylene glycol (PEG), etc.
Goals - The use of biodegradable NPs as drug transporters is one of the most promising strategies for the development of target specific controlled-release systems. The fundamental requirement for a biomaterial to be used in this sense is its biocompatibility, i.e., the ability to metabolize without any harmful effects. Systems of this type must be able to guarantee properties such as the ability to cross the body’s anatomical barriers, like blood-brain barrier (BBB), ophthalmic barrier, etc. and maintain the drug concentration over prolonged time at the site of action. In this research topic, we seek to highlight the most recent and state-of-the-art research on the regulation, structure, and function of the BBB and blood-cerebrospinal fluid barrier (BCSFB) in diseases of the CNS and the periphery. A particular focus on the expression and function of influx and efflux transporters and tight junction proteins at the brain barriers will be prioritized, given that these provide the biochemical and physical barriers to central nervous system(CNS) access, respectively.
Our collection welcomes submissions including, but not limited to, the following:
· Contributions from preclinical and clinical researchers focusing on the status of BBB in various brain diseases
· Role of polymeric NPs in the management of neurodegenerative disorders
· Role of functionalized NPs in the management of neurodegenerative disorders
· Porous nanoparticles in the management of neurodegenerative disorders and brain drug delivery
· Green nanoparticles in the management of neurodegenerative disorders
· Thermo-responsive/stimuli-responsive nanoparticles in brain tumors
· Nanoparticles for the diagnosis of brain tumors
· Nanoparticles used as imaging agents
Polymeric drug delivery systems have achieved great developments in the last two decades. These formulations or devices enable the introduction of therapeutic substances into the body. Biodegradable and bio-reducible polymers are the best choice for several new drug delivery systems. To understand the future and practical applications of these biodegradable and bioreducible polymers, we require further exploration of the recent developments in the field. In recent years, pharmaceutical research has focused on the development of nanotechnology systems applicable indifferent fields of medicine, especially in drug delivery. Currently, the use of biopolymers as nanoparticles (NPs) represents an alternative system with a huge potential for the targeted distribution of drugs or biological macromolecules in the body. Many polymers are used in the synthesis of nanoparticles (NPs), namely, polylactic acid (PLA), poly lactic-co-glycolic acid (PLGA), and polyethylene glycol (PEG), etc.
Goals - The use of biodegradable NPs as drug transporters is one of the most promising strategies for the development of target specific controlled-release systems. The fundamental requirement for a biomaterial to be used in this sense is its biocompatibility, i.e., the ability to metabolize without any harmful effects. Systems of this type must be able to guarantee properties such as the ability to cross the body’s anatomical barriers, like blood-brain barrier (BBB), ophthalmic barrier, etc. and maintain the drug concentration over prolonged time at the site of action. In this research topic, we seek to highlight the most recent and state-of-the-art research on the regulation, structure, and function of the BBB and blood-cerebrospinal fluid barrier (BCSFB) in diseases of the CNS and the periphery. A particular focus on the expression and function of influx and efflux transporters and tight junction proteins at the brain barriers will be prioritized, given that these provide the biochemical and physical barriers to central nervous system(CNS) access, respectively.
Our collection welcomes submissions including, but not limited to, the following:
· Contributions from preclinical and clinical researchers focusing on the status of BBB in various brain diseases
· Role of polymeric NPs in the management of neurodegenerative disorders
· Role of functionalized NPs in the management of neurodegenerative disorders
· Porous nanoparticles in the management of neurodegenerative disorders and brain drug delivery
· Green nanoparticles in the management of neurodegenerative disorders
· Thermo-responsive/stimuli-responsive nanoparticles in brain tumors
· Nanoparticles for the diagnosis of brain tumors
· Nanoparticles used as imaging agents